SCHEMBL7951904

SCHEMBL7951904

Cc1ccc(-c2nc(C)sc2C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
HPGD P15428 1/20 0.65
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
XBP1 P17861 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MYC P01106 1/20 0.40
WDR5 P61964 1/20 0.40
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090659 0.83 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL8188473 0.83 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2NPSR1MYC
SCHEMBL2093741 0.83 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2MAPTRARA
Ammonia Solution, Strong SCHEMBL8553360 0.82 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL8472083 0.81 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL8202114 0.80 ALDH1A1 (0.96) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL2303869 0.79 SMN1; SMN2 (0.70) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL28672395 0.79 SMN1; SMN2 (0.46) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL8188518 0.79 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2KDM4ELMNA
SCHEMBL15423314 0.79 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8834619-B2 Ink composition, ink for inkjet recording and inkjet recording method FUJIFILM CORPORATION (JP) 2014-09-16 US disclosed
US-8834619-B2 Ink composition, ink for inkjet recording and inkjet recording method FUJIFILM CORPORATION (JP) 2014-09-16 US disclosed
EP-2687565-A1 INK COMPOSITION, INKJET PRINTING INK, AND INKJET PRINTING METHOD FUJIFILM Corporation (JP) 2014-01-22 EP disclosed
US-20140013997-A1 INK COMPOSITION, INK FOR INKJET RECORDING AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2014-01-16 US disclosed
US-20140013997-A1 INK COMPOSITION, INK FOR INKJET RECORDING AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2014-01-16 US disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
US-7758683-B2 Ink composition, ink set and recording method FUJIFILM CORPORATION (JP) 2010-07-20 US disclosed
US-7758683-B2 Ink composition, ink set and recording method FUJIFILM CORPORATION (JP) 2010-07-20 US disclosed
US-7704311-B2 Ink composition, manufacturing method of ink, ink set, and recording method FUJIFILM CORPORATION (JP) 2010-04-27 US disclosed
US-7704311-B2 Ink composition, manufacturing method of ink, ink set, and recording method FUJIFILM CORPORATION (JP) 2010-04-27 US disclosed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO disclosed
US-7465344-B2 Ink for ink jet recording comprising print density improver, print density improver and method for improving print density FUJIFILM CORPORATION (JP) 2008-12-16 US disclosed
US-7465344-B2 Ink for ink jet recording comprising print density improver, print density improver and method for improving print density FUJIFILM CORPORATION (JP) 2008-12-16 US disclosed
US-7431760-B2 Ink and ink-jet recording ink FUJIFILM CORPORATION (JP) 2008-10-07 US disclosed
US-7431760-B2 Ink and ink-jet recording ink FUJIFILM CORPORATION (JP) 2008-10-07 US disclosed
WO-2008087611-A2 PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-24 WO disclosed
US-20070109376-A1 Ink composition, ink set and recording method FUJIFILM CORPORATION 2007-05-17 US disclosed
US-20070109376-A1 Ink composition, ink set and recording method FUJIFILM CORPORATION 2007-05-17 US disclosed
WO-2007046553-A1 INK COMPOSITION, MANUFACTURING METHOD OF INK, INK SET, AND RECORDING METHOD FUJIFILM CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR ALDH1A1 690/4885HPGD 2597/4885SMN1; SMN2 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.